Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

Abstract:

:Unlike the case with thrombosis, prognostic models for survival and leukemic transformation (LT) in essential thrombocythemia (ET) are not available. Among 605 patients with ET seen at our institution and followed for a median of 84 months, 155 died and LT was documented in 20 patients (3.3%). In a multivariable analysis, hemoglobin level below normal (females<120 g/l; males<135 g/l) was identified as an independent risk factor for both inferior survival and LT. Additional risk factors for survival included age > or =60 years, leukocyte count> or =15 x 10(9)/l, smoking, diabetes mellitus and thrombosis. For LT, platelet count> or =1000 x 10(9)/l but not cytoreductive therapy was flagged as an additional independent risk factor. In fact, four of the 20 patients (20%) with LT were untreated previously. We used the above information to construct prognostic models that effectively discriminated among low-, intermediate- and high-risk groups with respective median survivals of 278, 200 and 111 months (P<0.0001), and LT rates of 0.4, 4.8 and 6.5% (P=0.0009) respectively. Presence of JAK2V617F did not impact either survival or LT and mutational frequency was similar among the different risk groups.

journal_name

Leukemia

journal_title

Leukemia

authors

Gangat N,Wolanskyj AP,McClure RF,Li CY,Schwager S,Wu W,Tefferi A

doi

10.1038/sj.leu.2404500

subject

Has Abstract

pub_date

2007-02-01 00:00:00

pages

270-6

issue

2

eissn

0887-6924

issn

1476-5551

pii

2404500

journal_volume

21

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Giant parallel tube arrays (PTAs), a new type of lymphocyte inclusion.

    abstract::In a 56-year-old male patient, receiving chemotherapy after radical surgery for bladder carcinoma, an unusual type of cytoplasmic inclusion was discovered in about 30% of peripheral blood lymphocytes. This was a single, large (about 2 microns in diameter), round or ovoid body, darker than the nucleus and reddish-viole...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rozman M,Vives-Corrons JL,Germá JR,Colomer D,Villamor N,Rozman C

    更新日期:1994-12-01 00:00:00

  • The molecular characterization and clinical management of multiple myeloma in the post-genome era.

    abstract::Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is a powerful tool to globally analyze these changes to study cancer biology and clinical behavior. Despite overwhelming genomic chaos in multi...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.160

    authors: Zhou Y,Barlogie B,Shaughnessy JD Jr

    更新日期:2009-11-01 00:00:00

  • Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes.

    abstract::Multiple myeloma is a deadly hematopoietic malignancy. Despite therapeutic advances such as autologous stem cell transplantation and novel chemotherapeutics, multiple myeloma remains incurable. Multiple myeloma cell localization in the bone marrow and the cross-talk with the bone niche trigger dramatic alterations in ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2013.6

    authors: Colombo M,Mirandola L,Platonova N,Apicella L,Basile A,Figueroa AJ,Cobos E,Chiriva-Internati M,Chiaramonte R

    更新日期:2013-04-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract::This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.173

    authors: Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期:2017-12-01 00:00:00

  • Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.

    abstract::We have investigated the involvement of tumor suppressor genes (p53 and RB1) and dominantly acting oncogenes (Ras family genes) in BCR/ABL positive and negative chronic myeloproliferative disorders (CMPD) at different stages of the disease, including 26 cases of BCR/ABL+ chronic myeloid leukemia (CML) blast crisis, 9 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gaidano G,Guerrasio A,Serra A,Rege-Cambrin G,Saglio G

    更新日期:1994-04-01 00:00:00

  • Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993.

    abstract::A consecutive population-based series of 372 adult acute myeloid leukemias, successfully cytogenetically investigated at a single center between 1976 and 1993, is reported. All medical records were reviewed in order to ascertain the prognostic impact of karyotype, divided into three groups; favorable (t(8;21), t(15;17...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401788

    authors: Mauritzson N,Johansson B,Albin M,Rylander L,Billström R,Ahlgren T,Mikoczy Z,Strömberg U,Mitelman F,Hagmar L,Nilsson PG

    更新日期:2000-06-01 00:00:00

  • IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.

    abstract::Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dilloo D,Hanenberg H,Lion T,Burdach S

    更新日期:1995-03-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

    abstract::Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401851

    authors: Naito K,Takeshita A,Shigeno K,Nakamura S,Fujisawa S,Shinjo K,Yoshida H,Ohnishi K,Mori M,Terakawa S,Ohno R

    更新日期:2000-08-01 00:00:00

  • A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

    abstract::This study was undertaken to determine the efficacy and toxicity of a shorter schedule of fludarabine administration (30 mg/m2 i.v. daily for 3 days every 4 weeks) in patients with previously treated chronic lymphocytic leukemia (CLL). Eighty patients with previously treated advanced (Rai III-IV) (54%) or progressive ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Robertson LE,O'Brien S,Kantarjian H,Koller C,Beran M,Andreeff M,Lerner S,Plunkett W,Keating MJ

    更新日期:1995-09-01 00:00:00

  • Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.

    abstract::Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.342

    authors: Kampen KR,Ter Elst A,Mahmud H,Scherpen FJ,Diks SH,Peppelenbosch MP,de Haas V,Guryev V,de Bont ES

    更新日期:2014-03-01 00:00:00

  • SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

    abstract::Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.256

    authors: Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

    更新日期:2014-04-01 00:00:00

  • Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.

    abstract::Epidemiological studies have demonstrated an increased leukemia incidence following ionizing radiation exposure, but to date, the target cells and underlying mechanisms of radiation leukemogenesis remain largely unidentified. We engineered a mouse model carrying a different fluorescent marker on each chromosome 2, loc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0085-1

    authors: Verbiest T,Finnon R,Brown N,Cruz-Garcia L,Finnon P,O'Brien G,Ross E,Bouffler S,Scudamore CL,Badie C

    更新日期:2018-06-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract::The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402465

    authors: Shimada H,Ichikawa H,Ohki M

    更新日期:2002-05-01 00:00:00

  • The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.

    abstract::Resistance to anthracyclines is related to a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Resistance to this class of drugs may (partly) be reversed by modulating agents, as has been demonstrated in a variety of cell lines. However, it is unknown which modulators may be of clinical benefit in childh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401035

    authors: den Boer ML,Pieters R,Kazemier KM,Janka-Schaub GE,Henze G,Veerman AJ

    更新日期:1998-06-01 00:00:00

  • High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

    abstract::Acute myeloid leukemia (AML) is an aggressive malignancy, and development of new treatments to prolong remissions is warranted. Chimeric antigen receptor (CAR) T-cell therapies appear promising but on-target, off-tumor recognition of antigen in healthy tissues remains a concern. Here we isolated a high-affinity (HA) f...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.35

    authors: Lynn RC,Feng Y,Schutsky K,Poussin M,Kalota A,Dimitrov DS,Powell DJ Jr

    更新日期:2016-06-01 00:00:00

  • SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.

    abstract::Previously, we identified SETD2 loss-of-function mutations in 22% of MLL-rearranged (MLLr) acute leukemia patients, implicating a mechanism for cooperativity between SETD2 mutations and MLL fusions. However, the detailed mechanism of how SETD2-H3K36me3 downregulation accelerates MLLr leukemia remains unclear. Here, we...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.339

    authors: Bu J,Chen A,Yan X,He F,Dong Y,Zhou Y,He J,Zhan D,Lin P,Hayashi Y,Sun Y,Zhang Y,Xiao Z,Grimes HL,Wang QF,Huang G

    更新日期:2018-04-01 00:00:00

  • AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

    abstract::Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS pa...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2403814

    authors: Creutzig U,Reinhardt D,Diekamp S,Dworzak M,Stary J,Zimmermann M

    更新日期:2005-08-01 00:00:00

  • Translocation t(1;22) mimicking t(1;19) in a child with acute lymphoblastic leukemia as revealed by chromosome painting.

    abstract::The karyotype of a boy with acute lymphoblastic leukemia (ALL) presenting with numerical and structural chromosome aberrations as determined by Giemsa-banding was further investigated using chromosome painting (CP). A translocation t(11;18)(q23;q21) was verified by this approach, and gain of chromosome 21 material due...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Rieder H,Kolbus U,Koop U,Ludwig WD,Stollmann-Gibbels B,Fonatsch C

    更新日期:1993-10-01 00:00:00

  • A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia.

    abstract::Modern therapy for pediatric acute lymphoblastic leukemia (ALL) is based on the principle of risk stratification. One of the most important laboratory features used to accurately risk stratify patients is the presence of specific chromosomal translocation within the leukemic blasts. In this paper, we describe a multip...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401224

    authors: Scurto P,Hsu Rocha M,Kane JR,Williams WK,Haney DM,Conn WP,Shurtleff SA,Downing JR

    更新日期:1998-12-01 00:00:00

  • Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.111

    authors: Giles FJ,O'Dwyer M,Swords R

    更新日期:2009-10-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

    abstract::Bryostatin 1 is a macrocyclic lactone activator of protein kinase C which has displayed promising antileukemic potential in pre-clinical studies. We have assessed the effect of bryostatin 1 on the in vitro clonogenic response of leukemic myeloblasts obtained from 12 patients with acute non-lymphocytic leukemia to reco...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Grant S,Pettit GR,Howe C,McCrady C

    更新日期:1991-05-01 00:00:00

  • Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice.

    abstract::In this study neonatal mice expressing a GM-CSF transgene (GMT mice), and their normal littermate controls, were infected with Moloney murine leukemia virus (MoMLV) to examine in vivo tumorigenesis. By 200 days, all of the GMT mice had died whereas median survival had not been reached in the littermates (P < 0.0003). ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400614

    authors: Rasko JE,Metcalf D,Alexander B,Strasser A,Begley CG

    更新日期:1997-05-01 00:00:00

  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.

    abstract::Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects ...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/s41375-020-01016-0

    authors: Ludwig H,Boccadoro M,Moreau P,San-Miguel J,Cavo M,Pawlyn C,Zweegman S,Facon T,Driessen C,Hajek R,Dimopoulos MA,Gay F,Avet-Loiseau H,Terpos E,Zojer N,Mohty M,Mateos MV,Einsele H,Delforge M,Caers J,Weisel K,Jackso

    更新日期:2021-01-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract::Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.147

    authors: Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期:2016-11-01 00:00:00

  • Interleukin-2 and antibody to the T cell receptor regulate proliferation of a radiation leukemia virus-transformed T cell lymphoma.

    abstract::In this report, a Radiation leukemia virus-transformed murine T cell lymphoma is described which is dependent on the interleukin-2 (IL-2) growth factor for proliferation under single cell conditions of growth. It was isolated from a C57BL mouse which had been primed with the Radiation leukemia virus-induced thymoma, C...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: O'Neill HC

    更新日期:1988-02-01 00:00:00

  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00

  • MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

    abstract::MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.186

    authors: Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

    更新日期:2013-01-01 00:00:00

  • Four subclones with distinct immunoglobulin light chain phenotypes. (kappa+lambda+, kappa+, lambda+ and kappa-lambda-) from acute leukemia.

    abstract::A human acute lymphoblastic leukemia (ALL) cell line, BALM-9, was established from the peripheral blood specimen of a immunoglobin (lg) phenotype, the established BALM-9 cell line expressed both kappa and lambda light (L) chains simultaneously in a range of 30-80%. Two-color flow cytometric analysis demonstrated that ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Matsuo Y,Nakamura S,Ariyasu T,Terao R,Imajyo K,Tsubota T,Kuwahara K,Sakaguchi N

    更新日期:1996-04-01 00:00:00